To the Editor:

We read with interest the research article published by Ji and colleagues, in the *Journal of Hepatology*, showing that patients with metabolic-associated fatty liver disease (MAFLD) have a higher risk of COVID-19 disease progression and higher likelihood of abnormal liver blood tests from admission to discharge than patients without MAFLD.[@bib1] Given the absence of data on medical history of these patients, this persistence of liver blood test abnormalities could be either a mere reflection of pre-existing abnormalities related to MAFLD or could alternatively be due to a higher susceptibility of the fatty liver to SARS-CoV-2 infection.

We therefore investigated whether MAFLD is associated with altered liver expression of SARS-CoV-2 critical entry proteins. SARS-CoV-2 attaches to cells by binding to angiotensin-converting enzyme 2 (ACE2). The cellular protease transmembrane protease serine 2 (TMPRSS2) cleaves the SARS-CoV-2 spike protein, allowing fusion of cellular and viral membranes.[@bib2] ^,^ [@bib3] Moreover, in the HEK293 cell line, overexpressing human ACE2, SARS-CoV-2 enters through endocytosis with critical roles played by endocytosis-regulating protein phosphatidylinositol 3-phosphate 5-kinase (PIKFYVE).[@bib4] Finally, as described for SARS-CoV and MERS-CoV, cathepsin L is also critical for priming of the SARS-CoV-2 spike protein in lysosomes following entry through endocytosis.[@bib4]

We analysed the influence of MAFLD on liver gene expression of these 4 proteins implicated in SARS-CoV-2 infection by analysing public data from patients and from mice with MAFLD. In 2013, Ahrens and colleagues published microarray data obtained on human liver biopsies.[@bib5] ^,^ [@bib6] They made available transcriptomic data from 12 lean patients without MAFLD, 16 obese patients without MAFLD, 9 patients with simple steatosis and 17 patients with biopsy proven non-alcoholic steatohepatitis (NASH). Using these datasets, we observed that none of the genes necessary for SARS-CoV-2 infection was differentially expressed between lean or obese controls and patients with simple steatosis or with NASH ([Table 1](#tbl1){ref-type="table"} ).Table 1mRNA expression of SARS-CoV-2 infection critical genes in human liver biopsy.Gene nameLean without MAFLD (n = 12) *vs.* NASH (n = 17)Lean without MAFLD (n = 12) *vs.* simple steatosis (n = 9)Obese without MAFLD (n = 16) *vs.* simple steatosis (n = 9)Obese without MAFLD (n = 16) *vs.* NASH (n = 17)Lean and obese without MAFLD (n = 28) *vs.* simple steatosis or NASH (n = 26)Fold-changeadj. *p* valueFold-changeadj. *p* valueFold-changeadj. *p* valueFold-changeadj. *p* valueFold-changeadj. *p* value*ACE2*1.410.391.000.990.990.971.390.141.240.24*CTSL*0.980.961.100.691.040.730.920.670.990.95*TMPRSS2*0.850.720.780.570.870.640.940.950.880.60*PIKFYVE*1.030.930.770.940.850.110.920.640.940.53[^1][^2]

We performed the same analysis in a mouse dataset published by Xiong and colleagues.[@bib8] Similarly, we observed no increase in liver gene expression of the 4 proteins implicated in SARS-CoV-2 infection between MAFLD mice and control mice (data not shown).

In conclusion, MAFLD is not associated with changes in liver expression of genes implicated in SARS-CoV-2 infection. The observed persistence of liver blood test abnormalities reported by Ji and colleagues is thus likely not explained by increased hepatic SARS-CoV-2 uptake.
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[^1]: Human microarray data[@bib6] was made available by Ahrens and colleagues[@bib5] and reanalysed by us using Geo2R[@bib7] default settings. Geo2R is based on the \"Linear Models for Microarray Data\" R package that computes a moderated t-statistic for each gene and corresponding *p* value. Adjustment for multiple testing was performed using Benjamini and Hochberg\'s correction. *CSTL* gene encodes cathepsin L protein. Human transcriptomics data is available on GEO Dataset under the accession number [GSE48452](ncbi-geo:GSE48452){#intref0020}.

[^2]: MAFLD, metabolic-associated fatty liver disease; NASH, non-alcoholic steatohepatitis.
